“…Serotype O157:H7 is the dominant causative agent of STEC disease in the U.S. ( Riley et al, 1983 ; Eppinger et al, 2011 , 2013 ; Sanjar et al, 2014 ; Rusconi et al, 2016 ). However, the incidence of non-O157 infections that feature different somatic antigens has been steadily increasing in recent years ( Gould et al, 2013 ; Vishram et al, 2021 ; Glassman et al, 2022 ; Tarr et al, 2023 ). Among these, emerging serogroups O26, O45, O103, O111, O121, and O145 account for the majority of clinical non-O157 STEC infections in the US and are colloquially referred to as the “Big Six” ( Eklund et al, 2001 ; Johnson et al, 2006 ; Bettelheim, 2007 ; Hadler et al, 2011 ; Hegde et al, 2012 ; Gould et al, 2013 ; Vishram et al, 2021 ).…”